Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 8/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 6/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 6/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26653968 | 1.00 | IKBKB (0.39) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL26654141 | 1.00 | IKBKB (0.39) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL26654239 | 0.93 | PBRM1 (0.42) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL26804404 | 0.89 | PBRM1 (0.41) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL26654073 | 0.83 | PBRM1 (0.36) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL26654131 | 0.79 | PBRM1 (0.34) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL30658001 | 0.79 | PBRM1 (0.34) | IKBKBPBRM1SMARCA2SMARCA4CHUK | |
| SCHEMBL26653819 | 0.79 | PBRM1 (0.43) | IKBKBPBRM1SMARCA2SMARCA4CHEK2 | |
| SCHEMBL26653880 | 0.77 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL26653887 | 0.77 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | BRCA1, VHL, SF3B5 | IKBKB 2484/4885PBRM1 7/4885SMARCA2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.